Clinical Trial Update: The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes the PACMAN-Hu19 trial evaluating the safety and feasibility of locally produced, CD19-targeted CAR T-cell therapy for relap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Drugs mentioned

• Hu19 CAR-T cell therapy (CD19-targeted CAR T-cell therapy)

Snippet

Sponsor: Princess Maxima Center for Pediatric Oncology | Conditions: Leukemia, Lymphoma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING